Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients.

Butow, PN; Best, MC; Davies, G; Schlub, T; Napier, CE; Bartley, N; Ballinger, ML; Juraskova, I; Meiser, B; Goldstein, D; Biesecker, B; Thomas, DM; members of the PiGeOn Project,

Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients.

Butow, PN Best, MC Davies, G Schlub, T Napier, CE Bartley, N

Ballinger, ML Juraskova, I Meiser, B Goldstein, D Biesecker, B Thomas, DM members of the PiGeOn Project,

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Patient Education and Counseling, 2022, 105, (7), pp. 2206-2216
Issue Date:: 2022-07

Closed Access

	Filename	Description	Size
	1-s2.0-S0738399122000349-main.pdf		827.8 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Butow, PN
dc.contributor.author	Best, MC
dc.contributor.author	Davies, G
dc.contributor.author	Schlub, T
dc.contributor.author	Napier, CE
dc.contributor.author	Bartley, N https://orcid.org/0000-0001-9052-1616
dc.contributor.author	Ballinger, ML
dc.contributor.author	Juraskova, I
dc.contributor.author	Meiser, B
dc.contributor.author	Goldstein, D
dc.contributor.author	Biesecker, B
dc.contributor.author	Thomas, DM
dc.contributor.author	members of the PiGeOn Project,
dc.date.accessioned	2022-11-24T04:14:42Z
dc.date.available	2022-01-21
dc.date.available	2022-11-24T04:14:42Z
dc.date.issued	2022-07
dc.identifier.citation	Patient Education and Counseling, 2022, 105, (7), pp. 2206-2216
dc.identifier.issn	0738-3991
dc.identifier.issn	1873-5134
dc.identifier.uri	http://hdl.handle.net/10453/163720
dc.description.abstract	OBJECTIVE: Comprehensive tumor genomic profiling (CTGP) is increasingly used to personalize treatments, providing hope, but potentially disappointment, for patients. We explored psychological outcomes in patients with advanced, incurable cancer, after receiving CTGP results. METHODS: Participants with advanced, incurable cancer (n = 560, mean age 56, 43% university educated) in this longitudinal substudy of the Molecular Screening and Therapeutics Program (MoST), completed questionnaires before and after receiving CGP results. MoST participants, recruited from Australian oncology clinics, undergo CTGP, and if there are actionable findings, are offered treatment in a related therapeutic trial if available. RESULTS: Patients who received actionable results, (n = 356, 64%) had lower gene-related distress (MICRA) (p < 0.001) and Impact of Events scores (p = 0.039) than patients with non-actionable results. Those with actionable results offered ensured access to tailored treatment (n = 151) reported lower anxiety (p = 0.002) and depressive symptoms (p = 0.01) and greater hope (p = 0.002) than those not offered. Positive attitudes towards uncertainty and higher self-efficacy for coping with results were associated with lower psychological distress and uncertainty, and higher hope and satisfaction with the decision to have CTGP (ps=0.001-0.047). Those with higher knowledge reported greater anxiety (p = 0.034). CONCLUSION: Receiving a non-actionable CTGP result, or an actionable result without ensured access to treatment, may cause increased distress in advanced cancer patients. Coping style was also associated with distress. PRACTICE IMPLICATIONS: Pre-testing assessment and counseling addressing attitudes toward uncertainty and self-efficacy, and post-CTGP result support for patients receiving a non-actionable result or who receive an actionable results without ensured access to treatment, may benefit patients.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Patient Education and Counseling
dc.relation.isbasedon	10.1016/j.pec.2022.01.011
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Public Health
dc.subject.mesh	Anxiety
dc.subject.mesh	Australia
dc.subject.mesh	Genomics
dc.subject.mesh	Humans
dc.subject.mesh	Middle Aged
dc.subject.mesh	Neoplasms
dc.subject.mesh	Uncertainty
dc.subject.mesh	Anxiety
dc.subject.mesh	Australia
dc.subject.mesh	Genomics
dc.subject.mesh	Humans
dc.subject.mesh	Middle Aged
dc.subject.mesh	Neoplasms
dc.subject.mesh	Uncertainty
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Uncertainty
dc.subject.mesh	Anxiety
dc.subject.mesh	Genomics
dc.subject.mesh	Middle Aged
dc.subject.mesh	Australia
dc.title	Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients.
dc.type	Journal Article
utslib.citation.volume	105
utslib.location.activity	Ireland
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-11-24T04:14:40Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	105
utslib.citation.issue	7

Abstract:

OBJECTIVE: Comprehensive tumor genomic profiling (CTGP) is increasingly used to personalize treatments, providing hope, but potentially disappointment, for patients. We explored psychological outcomes in patients with advanced, incurable cancer, after receiving CTGP results. METHODS: Participants with advanced, incurable cancer (n = 560, mean age 56, 43% university educated) in this longitudinal substudy of the Molecular Screening and Therapeutics Program (MoST), completed questionnaires before and after receiving CGP results. MoST participants, recruited from Australian oncology clinics, undergo CTGP, and if there are actionable findings, are offered treatment in a related therapeutic trial if available. RESULTS: Patients who received actionable results, (n = 356, 64%) had lower gene-related distress (MICRA) (p < 0.001) and Impact of Events scores (p = 0.039) than patients with non-actionable results. Those with actionable results offered ensured access to tailored treatment (n = 151) reported lower anxiety (p = 0.002) and depressive symptoms (p = 0.01) and greater hope (p = 0.002) than those not offered. Positive attitudes towards uncertainty and higher self-efficacy for coping with results were associated with lower psychological distress and uncertainty, and higher hope and satisfaction with the decision to have CTGP (ps=0.001-0.047). Those with higher knowledge reported greater anxiety (p = 0.034). CONCLUSION: Receiving a non-actionable CTGP result, or an actionable result without ensured access to treatment, may cause increased distress in advanced cancer patients. Coping style was also associated with distress. PRACTICE IMPLICATIONS: Pre-testing assessment and counseling addressing attitudes toward uncertainty and self-efficacy, and post-CTGP result support for patients receiving a non-actionable result or who receive an actionable results without ensured access to treatment, may benefit patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/163720